We found that ESR2 (estrogen receptor β) expression within the breast cancer stroma was not significantly associated with patient outcome (p = 0.9337, Fig 6A) indicative that miR–92 may be functioning via the regulation of alternative targets. The gene discussed is ESR2; the disease is breast carcinoma.